Semaglutide vs Tirzepatide: Which Molecule Fits You

Before you compare providers, compare molecules. Almost every telehealth clinic on our board sells semaglutide, tirzepatide, or both — and the choice between the two active ingredients shapes your likely results more than the storefront you buy from. Here is what the trial evidence actually says, and how to turn it into a decision.

The mechanism, in one paragraph

Semaglutide — the molecule in Wegovy — is a GLP-1 receptor agonist: it mimics one gut hormone that curbs appetite and slows gastric emptying⁴. Tirzepatide — the molecule in Zepbound — is a dual agonist, hitting both the GLP-1 and GIP receptors⁵. That second target is the headline structural difference, and it tracks with the difference you see in the trial numbers.

What the trials show

The pivotal obesity studies were run separately, not head-to-head, so treat cross-trial comparisons as directional rather than exact:

- **Semaglutide (STEP 1):** mean weight reduction of roughly 15% of body weight over 68 weeks, versus about 2.4% on placebo¹. - **Tirzepatide (SURMOUNT-1):** up to about 21% at the 15 mg dose over 72 weeks².

There is also one direct head-to-head, though it was run in type 2 diabetes at the diabetes doses — not the higher obesity doses. In SURPASS-2, tirzepatide produced greater reductions in A1C and body weight than semaglutide 1 mg³. It is the best apples-to-apples signal available, with the caveat that it studied a different population and dose than weight-management care.

Reading the trade-off honestly

On the trial evidence, tirzepatide tends to deliver larger average weight loss. That is the case for choosing it. But "larger on average" is not "better for everyone":

- **Tolerability is individual.** Both molecules share the same GI side-effect profile — nausea, and the boxed thyroid C-cell tumor warning on both labels⁴⁵. Some people tolerate one better than the other. - **Cost usually favors semaglutide.** Across our board, semaglutide is typically the lower-priced molecule. If budget is the binding constraint, the cheaper drug that you actually stay on beats the stronger drug you abandon. - **Optionality has value.** Providers that carry both let you switch without re-onboarding if your response or tolerance changes.

How to decide

Ask your prescriber for **tirzepatide** if maximum average weight loss is the priority and cost is manageable. Ask for **semaglutide** if you want the longer real-world track record, a lower monthly price, or you are starting cautiously. Either way, this is a clinical decision to make with the provider — the Desk scores providers, not your prescription.

Turning the molecule choice into a provider choice

Once you know which molecule you want, filter the board to providers that carry it — ideally both, for flexibility. Our top-scored CoreAge Rx offers both semaglutide and tirzepatide on one account, and you can line it up against the field on the comparison desk or the alternatives view. If the brand-versus-compounded question is still open, read compounded vs brand-name GLP-1 next; if needles are the sticking point, see injections vs oral GLP-1.